DIABETES CIES SEARCH ENGINE [SELECTED WEBSITES]

Thursday, June 3, 2010

GENFIT : Two major pre-diabetes clinical trials within the IT-Diab Program

GENFITMay 31, 2010 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, announces that it has received approval from the French medical agencies to initiate the enrollment of patients in two major clinical trials in pre-diabetes and the early stages of diabetes, as part of its IT-Diab program.
The DECODIAB (DEpistage et COmpréhension du préDIABète) study, where a cohort of 500 hyperglycemic subjects will be assessed prospectively over a 5 year period for their conversion to Type 2 Diabetes, is led by Pr. Bertrand Cariou (Endocrinology-Diabetology Department, Thorax Institute/U915 INSERM, CHU Nantes, France). It will offer the opportunity to identify and validate in humans new biomarkers of -cell dysfunction in a population prone to develop Type 2 Diabetes. Enrollment for the DECODIAB trial is expected to begin in June 2010... [PDF] GENFIT's Press Release -

Thursday, May 27, 2010

Home Diagnostics, Inc. and Cellnovo : Strategic Alliance

CellnovoMay 6, 2010 – Building on a shared vision to simplify diabetes management worldwide, Cellnovo, a London-based medical device company, and Home Diagnostics, Inc., a leader in diabetes products, announced a strategic alliance that involves integrating technologies and developing distribution opportunities for Cellnovo’s insulin patch pumps.

Home Diagnostics, Inc.The partnership allows both companies to accelerate their growth and has the potential to transform the pump industry. The first phase of the agreement calls for the inclusion of Home Diagnostics TRUE™ blood glucose technology in the Cellnovo wireless mobile handset. The companies will also begin exploring ways to leverage Home Diagnostics’ distribution network to expand Cellnovo’s presence in the United States and other countries... [PDF] Home Diagnostics' Press Release -

Wednesday, May 12, 2010

IRIDEX : First Commercial Shipment of New IQ 532(TM) Laser Systems

IRIDEXApril 30, 2010 - IRIDEX Corporation, (Nasdaq: IRIX) announced the commencement of commercial shipment of the IQ 532 laser systems. The IQ 532 is a high-power, 532 nm, dual port multi-purpose laser system for use by ophthalmologists to treat sight-threatening eye diseases such as diabetic retinopathy, age-related macular degeneration and glaucoma; and for use by otolaryngologists to correct certain types of conductive hearing loss.

"The time and effort we invested to perfect our core system platform and obtain regulatory approval for a family of laser products has made it possible to introduce the IQ 532 green laser within one year of shipping the IQ 577 yellow laser... IRIDEX's Press Release -

Pro-Tect Pharmaceuticals : Revolutionary Drug Delivery Patents

Pro-Tect PharmaceuticalsApril 26, 2010 - Pro-Tect Pharmaceuticals, Inc. (PRTT) announced that it has completed the acquisition of multiple patents and patents-pending from Nectid, Inc., that enable three revolutionary drug delivery technologies.

The acquired patents would enable Pro-Tect to provide efficient, effective drug delivery platforms for three essential yet currently unmet needs:

- A gastro-retentive platform for drugs that otherwise have short time windows for absorption
- An abuse deterrent platform for prescription drugs that are prone to abuse, especially narcotic pain-killers
- A once-daily platform that allows two or more drugs commonly taken in combination to be delivered via a single dose with fewer side effects

"It's incredible to us that no one previously has developed delivery platforms that meet such obvious and crucial needs," said Pro-Tect CEO Bill Abajian. "In particular, the ability to treat long-term pain without patients becoming opioid-addicted would fundamentally change pain management. We're excited that the success of these drug delivery platforms could not just improve the quality of life for so many people, but actually save lives."

Nectid
In the near term, Pro-Tect intends to proceed with a comprehensive program to develop and commercialize once-daily drugs for diabetic neuropathic pain, fibromyalgia, postherpetic neuralgia and epilepsy... Pro-Tect Pharmaceuticals' Press Release -

Kyowa Hakko Kirin and Reata Pharmaceuticals : licensing agreement on bardoxolone methyl in Japan and other selected Asian markets

Reata PharmaceuticalsJanuary 7, 2010 - Bardoxolone methyl is a small molecule compound currently being developed in Phase II clinical trials in the US by Reata Pharmaceuticals for the treatment of chronic kidney disease in diabetic patients.- Reata Pharmaceuticals, Inc. (Reata) and Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin) announced that they have entered into a licensing agreement that provides Kyowa Hakko Kirin with the exclusive rights to develop and commercialize Reata's lead compound, bardoxolone methyl (bardoxolone), in Japan and other selected Asian markets. Under the terms of the agreement, Reata is eligible to receive up to $272 million in up-front fees and milestone payments, in addition to double-digit royalties.

Kyowa Hakko Kirin Co., Ltd.
Bardoxolone activates the Nrf2 gene, which controls the production of over 250 antioxidant and detoxification proteins. Activation of Nrf2 protects tissues by increasing cellular antioxidant content and suppressing inflammatory signaling pathways. It is now known that chronic "metabolic inflammation" promotes Type 2 diabetes and its complications, including cardiovascular disease and chronic kidney disease (CKD).

In two Phase 2 trials, bardoxolone significantly improved renal function in Type 2 diabetic patients with advanced CKD... Reata Pharmaceuticals' Press Release - Kyowa Hakko Kirin's Press Release -

Tuesday, May 4, 2010

Anthera Pharmaceuticals : VARESPLADIB SHOWED EARLY BENEFIT IN DIABETIC PATIENT POPULATION

nthera PharmaceuticalsMay 3, 2010 - ANTHERA PHARMACEUTICALS ANNOUNCES ADDITIONAL DATA FROM FRANCIS STUDY – Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, announced detailed results from a new biomarker analysis of the FRANCIS study. FRANCIS examined the effects of once-daily varespladib vs. placebo as an adjunct treatment to high-dose atorvastatin and standard of care on inflammatory biomarkers known to be predictive of secondary cardiovascular events in patients with a recent acute coronary syndrome (ACS). This new analysis examines the anti-inflammatory effects of varespladib, an inhibitor of secretory phospholipase A2 (sPLA2), in diabetic patients with a recent ACS... Anthera Pharmaceuticals' Press Release -

Tuesday, April 27, 2010

Bayer Diabetes Care : introduction of the DIDGET™ blood glucose monitoring system in the United States

Bayer Diabetes CareApril 26, 2010 - Transforms Kids’ Diabetes Experience by Linking Play with Purpose – Bayer Diabetes Care announced the introduction of the DIDGET™ blood glucose monitoring system in the United States. The DIDGET meter is unique because it is the only blood glucose meter that connects directly to Nintendo DS™ and DS Lite gaming systems to help kids manage a lifelong disease by rewarding them for building consistent testing habits and meeting personalized blood glucose target ranges. Bayer’s DIDGET meter is now available for purchase in the US through CVS.com, Drugstore.com and Walgreens.com.
Bayer’s DIDGET meter links play with purpose for children with diabetes by tapping into kids’ existing passion for handheld gaming. The DIDGET meter positively reinforces consistent blood glucose testing habits by awarding points that kids can use to unlock new game levels and customize their gaming experience.
“As the first meter truly designed with kids in mind, the DIDGET meter can transform a child’s blood sugar testing experience from something they have to do into something they want to do,”... [PDF] Bayer Diabetes Care's Press Release -

MannKind Corporation : Follow-up Safety Data Show AFREZZA(TM) Comparable to Standard Antidiabetic Therapy in Lung Function Tests

MannKind CorporationApr 23, 2010 - Follow-up Study with Investigational Diabetes Therapy Presented at the American Association of Clinical Endocrinologists 19th Annual Meeting -Pulmonary function test results (PFTs) in patients treated with AFREZZA TM (insulin human [rDNA origin]) Inhalation Powder, a well-tolerated, ultra rapid acting insulin, at follow-up measurements were similar to PFT results observed in patients receiving standard antidiabetic therapy, according to data presented today at the American Association of Clinical Endocrinologists 19th Annual Meeting (Poster #267). Results from the follow-up study suggest that the pattern and magnitude of changes in lung function associated with the use of AFREZZA in patients with Type 1 and Type 2 diabetes are not likely due to any structural alterations in the lungs and are not clinically meaningful.

"Our findings add to the growing body of clinical evidence that indicates AFREZZA is comparable to standard of care insulin therapy in terms of lung safety," ...

...

...AFREZZA is a novel, ultra rapid acting mealtime insulin therapy being developed by MannKind Corporation for the treatment of adult patients with Type 1 and Type 2 diabetes for the control of hyperglycemia. It is a drug-device combination product, consisting of AFREZZA Inhalation Powder pre-metered into single use dose cartridges and the light, discreet and easy-to-use AFREZZA Inhaler. Administered at the start of a meal, AFREZZA dissolves immediately upon inhalation and delivers insulin quickly to the blood stream. Peak insulin levels are achieved within 12 to 14 minutes of administration, mimicking the release of meal-time insulin observed in healthy individuals. To date, the AFREZZA clinical program has involved 49 different studies and over 5,000 adult patients... MannKind's Press Release -

Amylin, Lilly and Alkermes Submit Reply to FDA Complete Response Letter for BYDUREON(TM)

Apr 22, 2010 - Classification of Submission and New PDUFA Action Date Expected Within 14 Days, per FDA Guidelines -Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) announced that the companies have submitted their reply to a complete response letter issued last month by the U.S. Food and Drug Administration (FDA) after review of the New Drug Application (NDA) submission for BYDUREON™ (exenatide for extended-release injectable suspension). In accordance with its guidelines, the FDA is expected to classify the complete response as a Class 1 or Class 2 resubmission, and also provide the companies with an updated Prescription Drug User Fee Act (PDUFA) target action date within the next two weeks.

Amylin Pharmaceuticals, Inc.
The companies' reply addresses requests from the FDA primarily related to finalization of the product labeling with accompanying Risk Evaluation and Mitigation Strategy (REMS) and clarification of existing manufacturing processes.

Eli Lilly and CompanyThe FDA's complete response letter did not request new pre-clinical or clinical trials, nor did it contain requests related to the December 2009 observations from the FDA's pre-approval inspection at the Ohio manufacturing facility. All of these observations have been addressed.

Alkermes, Inc."The companies have worked diligently and quickly over the last few weeks to submit a complete response and are confident we addressed the requests that were outlined by the FDA,"...

...

...BYDUREON (pronounced by-DUR-ee-on) is the proposed brand name for exenatide once weekly. It is an investigational, extended-release medication for type 2 diabetes designed to deliver continuous therapeutic levels of exenatide in a single weekly dose. BYDUREON is a once-weekly formulation of exenatide, the active ingredient in BYETTA(R) (exenatide) injection, which has been available in the U.S. since June 2005 and is used in approximately 60 countries worldwide to improve glycemic control in adults with type 2 diabetes. BYDUREON and BYETTA belong to the glucagon-like peptide-1 (GLP-1) receptor agonist class of medications... Alkermes' Press Release - Eli Lilly's Press Release - Amylin's Press Release -

Catabasis Pharmaceuticals : $39.6 Million Series A Funding

Catabasis PharmaceuticalsApril 21, 2010 - Breakthrough Approach to Treating Metabolic and Inflammatory Conditions – Catabasis Pharmaceuticals, a biopharmaceutical company developing novel therapeutics for the treatment of inflammatory and metabolic diseases, announced it has completed a $39.6 million Series A financing led by SV Life Sciences, Clarus Ventures, and MedImmune Ventures. Also participating in the round is Advanced Technology Ventures. Proceeds from the financing will be used to advance Catabasis’ lead program targeting type 2 diabetes, and to further the development of the company’s proprietary platform technology in additional inflammatory and metabolic diseases... [PDF] Catabasis Pharmaceuticals' Press Release -

Sanofi-aventis : Once Daily Lixisenatide (AVE 0010) Given as Monotherapy Successfully Meets Phase III Study Endpoints in Diabetes

Sanofi-aventisApril 15, 2010 - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced that the results of the first, placebo-controlled study of the GetGoal Phase III clinical trial program showed lixisenatide (AVE0010), a once-daily GLP-1 agonist, significantly reduced HbA1c vs. placebo with more patients achieving HbA1c...

...

...Lixisenatide, a GLP-1, Glucagon-like peptide-1 agonist, is under development for the treatment of patients with type 2 diabetes mellitus. In the Phase IIb study, once-a-day dosing with lixisenatide was shown to be effective in lowering blood sugar with a good tolerability... Sanofi-Aventis' Press Relase -